2021
Karo Pharma resolves on sale of own shares
Under the the authorization from the 2021 Annual General Meeting, the Board of Directors has resolved to sell up to…
Interim report Q1 2021
January – March Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period. The organic…
Karo Pharma completes the acquisition of the brand portfolio from Teva Pharmaceuticals
Karo Pharma Aktiebolag (“Karo”) today announces that the acquisition of the European OTC brand portfolio from Teva Pharmaceuticals (Teva) for…
Karo Pharma publishes the 2020 annual report
Today, on 30 March 2021, Karo Pharma is publishing its annual report for 2020 on the company’s website, www.karohealthcare.com. For…
Year-end report 2020
Q4, October – December Net sales amounted to MSEK 721.2 (649.3). This corresponds to an increase of 11% for the…
Karo Pharma acquires European OTC brand portfolio from Teva Pharmaceuticals
Karo Pharma Aktiebolag (“Karo”) today announces the acquisition of an OTC brand portfolio containing Flux®, Decubal®, Lactocare®, Apobase®, Dailycare® and…